XJ Biotech specializes in the in vitro production of platelets derived from stem cells, addressing the critical shortage of platelets needed for treating cancer, liver disease, and other hematological conditions. The company also develops targeted therapies for diseases associated with platelet dysfunction, enhancing treatment options for patients with thrombocytopenia and related disorders.
Funding
Funding not disclosed
Founders
Product
Problem
There is a critical shortage of platelets needed for treating various conditions such as cancer, liver disease, and hematological disorders. Current methods of obtaining platelets rely heavily on blood donations, which can be limited and pose logistical challenges.
Solution
XJ Biotech specializes in the in vitro production of platelets derived from stem cells, offering a scalable and reliable alternative to traditional blood donation. By leveraging stem cell technology, the company aims to address the platelet shortage and provide a consistent supply for therapeutic applications. In addition to platelet production, XJ Biotech is developing targeted therapies for diseases associated with platelet dysfunction, expanding treatment options for patients with thrombocytopenia and related disorders. The company's focus is on advancing cell therapies and drug development related to blood regeneration.
Target Audience
The primary customers are hospitals, blood banks, and research institutions that require a consistent and reliable supply of platelets for patient care and research purposes.
Features
- In vitro production of platelets from stem cells
- Targeted therapies for platelet dysfunction-related diseases
- Stem cell-based approach for cell therapy and drug development
- Focus on blood regeneration technologies
- Addressing platelet shortages in cancer, liver disease, and hematological conditions